GlassScriptPhysician profile
Niyati Goradia
NPI 1053866467
$2,445.45
in general payments reported to CMS, 2019-2025
32 companies · $140 in 2025
The $140 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $623 · 2023: $618 · 2024: $1,064 · 2025: $140.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,297 · Consulting Fee: $525.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,297.17 |
| Consulting Fee | $525.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $544.43 | 2024 | Lynparza |
| Servier Pharmaceuticals LLC | $433.92 | 2022 | |
| Exelixis INC. | $351.66 | 2023-2024 | Cabometyx |
| Janssen Biotech, INC. | $117.05 | 2023-2025 | Carvykti, Darzalex, Tecvayli |
| Celltrion USA INC. | $114.40 | 2023 | Vegzelma |
| Novartis Pharmaceuticals Corporation | $84.01 | 2023-2025 | |
| Foundation Medicine, INC. | $81.95 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $61.02 | 2022-2023 | |
| Pfizer INC. | $56.61 | 2023-2024 | |
| Abbvie INC. | $55.83 | 2023-2025 | |
| Incyte Corporation | $55.66 | 2022-2024 | Jakafi |
| Sumitomo Pharma America, INC. | $50.34 | 2023-2024 | Orgovyx |
| Beigene USA, INC. | $48.37 | 2024 | Brukinsa |
| Amgen INC. | $44.27 | 2023 | Xgeva, Vectibix, Nplate |
| Glaxosmithkline, LLC. | $32.84 | 2023-2024 | Ojjaara |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $32.63 | 2023-2024 | Enhertu |
| Genentech USA, INC. | $29.20 | 2024-2025 | Polivy, Venclexta, Columvi |
| Cti Biopharma Corp. | $29.08 | 2023 | Vonjo |
| Taiho Oncology, INC. | $18.64 | 2023 | |
| Celgene Corporation | $18.39 | 2025 | Opdualag |
| Eisai INC. | $18.17 | 2023 | |
| Emd Serono, INC. | $16.88 | 2023 | Bavencio |
| Astellas Pharma US INC | $16.39 | 2024 | Xospata |
| Kite Pharma, INC. | $16.14 | 2025 | Yescarta |
| Array Biopharma INC | $15.99 | 2024 | Braftovi, Lorbrena |
| Karyopharm Therapeutics INC. | $15.84 | 2023 | Xpovio |
| Morphosys, US INC. | $15.71 | 2022 | |
| Alexion Pharmaceuticals, INC. | $14.82 | 2023 | Ultomiris |
| E.R. Squibb & Sons, L.L.C. | $14.66 | 2023 | Opdivo |
| Seagen INC. | $14.09 | 2022 | |
| Baxter Healthcare | $13.23 | 2022 | |
| Puma Biotechnology, INC. | $13.23 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Niyati Goradia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.